期刊文献+

4-甲基-2-(3-甲酰基-4-羟基苯基)-5-噻唑甲酸乙酯的合成工艺改进 被引量:1

Synthesis of 4-Methyl-2-(3-formyl-4-hydroxyphenyl)-5-thiazole Formic Acid Ethyl Ester
下载PDF
导出
摘要 以对羟基苯甲醛为原料,经氰化、硫代酰胺化、环合、甲酰化合成得非布索坦中间体4-甲基-2-(3-甲酰基-4-羟基苯基)-5-噻唑甲酸乙酯。对合成工艺进行了改进,总收率52.4%。合成方法简单易行,对仪器设备腐蚀性小,操作安全,节约成本,适于工业化生产。 4-Methyl-2-(3-formyl-4-hydroxyphenyl)-5-thiazole formic acid ethyl ester was synthesized by using p-hydroxybenzaldehyde as raw material through the following reactions including cyanide, thioamide, cyclization, and formylation reaction. A total yield of 52.4% was achieved due to improvement on the technology of febuxostat intermediate synthesis. In addition, the structures of the intermediates and target compound were confirmed by 1H NMR. The research results indicated that this synthesis method had the advantages including simple, less corrosive to equipment, high safety and low cost, and was suitable for industrial production.
出处 《精细化工中间体》 CAS 2015年第5期22-25,共4页 Fine Chemical Intermediates
基金 佳木斯大学研究生科技创新重点项目(LZZ2014_031) 黑龙江省大学生创新创业训练计划项目(201410222013)
关键词 对羟基苯甲醛 5-噻唑甲酸乙酯 硫氢化钠 冰乙酸 工艺改进 p-hydroxybenzaldehyde 5-thiazole formic acid ethyl ester acetic acid process improvement
  • 相关文献

参考文献16

二级参考文献70

  • 1张媛.抗痛风药Febuxostat[J].药学进展,2005,29(3):141-142. 被引量:8
  • 2王春辉,李松.黄嘌呤氧化酶抑制剂的研究进展[J].国外医学(药学分册),2006,33(5):351-353. 被引量:16
  • 3YAMAMOTO T. Development of antihyperuricemic candidates[J]. Nippon Rinsho, 2003, 61 ( S1 ) : 209 - 212.
  • 4TAKANO Y, HASE-AOKI K, HORIUCHI H, et al. Selectivity of febuxostat, a novel nonpurine inhibitor of xanthine oxldase/xanthine dehydyogenase[J]. Life Sci, 2005, 76(16) : 1835 - 1847.
  • 5BECKER M A, SCHUMACHER H R Jr, WORTMANN R L. Febuxostat compared with aUopurinol in patients with hyperurlcemia and gout [ J ]. N Engl J IVied, 2005, 353(23) :2450 - 2461.
  • 6BECKER M A, SCHUMACHER H R Jr, WORTMANN R L. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a 28-day, multicenter, phase Ⅱ, randomized, double-blind, placebo controlled dose-response clinical trial examining safety and efficacy in patients with gout [ J ]. Arthritis Rheum, 2005, 52(3) :916 - 923.
  • 7POHAR S, MURPHY G. Febuxostat for prevention of gout attacks [ J ]. Issues Emerg Health Technol, 2006, 87(8) : 1 - 4.
  • 8TAYLOR W :j, SCHUMACHER H R :Jr. Assessment of outcome in clinical trials of gout-a review of current measures [ :J ]. Rheumatology, 2007, 46 ( 12 ) : 1751 - 1756.
  • 9BRYAN T, EMMERSON M D. The treatment of gout[J]. Drug Ther, 1996, 334(7) : 445 - 451.
  • 10VERGE J P, ROFFEY P. Antiprotozoal thiazoles. 2- (5-nitro-2-thienyl)-thiazoles[J] .J Med Chem, 1975, 18(8) :794.

共引文献49

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部